Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.fatetherapeutics.com
Fate Therapeutics, Inc. News Releases
Get the latest updates from Fate Therapeutics, Inc. News Releases directly as they happen.
Follow now 66 followers
Latest posts
Last updated 1 day ago
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
1 day ago
As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory...
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
14 days ago
SAN DIEGO , Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
25 days ago
SAN DIEGO , Oct. 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
about 2 months ago
SAN DIEGO , Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...
Fate Therapeutics to Present at Upcoming Investor Conferences
2 months ago
SAN DIEGO , Aug. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
3 months ago
First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
3 months ago
SAN DIEGO , Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
4 months ago
SAN DIEGO , July 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
5 months ago
All three patients treated with FT819 following fludarabine-free conditioning regimen for severe...
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
5 months ago
SAN DIEGO , May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
5 months ago
Oral presentation of clinical data from FT819 Phase 1 study highlights safety...
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
5 months ago
Oral presentation of clinical data from FT819 Phase 1 study highlights safety...